{"id":36976,"date":"2018-03-06T09:00:00","date_gmt":"2018-03-06T07:00:00","guid":{"rendered":"https:\/\/www.ipsen.com\/?post_type=press_release&#038;p=36976"},"modified":"2023-09-06T18:43:27","modified_gmt":"2023-09-06T16:43:27","slug":"ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/","title":{"rendered":"Ipsen annonce la pr\u00e9sentation de 18 posters lors de la 15e conf\u00e9rence annuelle de l\u2019ENETS"},"content":{"rendered":"<p>Paris (France), 6 mars 2018 \u2013 Ipsen (Euronext : IPN ; ADR : IPSEY) a annonc\u00e9 aujourd\u2019hui que le<br \/>\nlanr\u00e9otide (Somatuline\u00ae), le cabozantinib (Cabometyx\u00ae) et le t\u00e9lotristat \u00e9thyl (Xermelo\u00ae), ainsi que<br \/>\ndes recherches sur le traitement des TNE dans des conditions r\u00e9elles, la m\u00e9decine nucl\u00e9aire et<br \/>\nl\u2019imagerie, et l\u2019exp\u00e9rience patient, feraient l\u2019objet de 18 posters lors de la 15e conf\u00e9rence annuelle<br \/>\nENETS (European Neuroendocrine Tumor Society) qui se tiendra du 7 au 9 mars \u00e0 Barcelone<br \/>\n(Espagne). Les posters seront pr\u00e9sent\u00e9s dans le cadre de deux sessions : le 8 mars de 15h20 \u00e0<br \/>\n16h05 (CET) et le 9 mars de 10h40 \u00e0 11h30 (CET).<\/p>\n<p>\u00ab<em> Ipsen poursuit son engagement \u00e0 faire avancer la recherche et la formation afin de mieux<\/em><br \/>\n<em>comprendre et d\u2019am\u00e9liorer en permanence les options th\u00e9rapeutiques pour les patients atteints de<\/em><br \/>\n<em>tumeurs neuroendocrines (TNE). Notre objectif est d\u2019optimiser les r\u00e9sultats des traitements et la<\/em><br \/>\n<em>qualit\u00e9 de vie de ces patients. Nous sommes heureux de pr\u00e9senter des donn\u00e9es scientifiques et<\/em><br \/>\n<em>cliniques prometteuses sur notre portefeuille de produits dans les domaines des tumeurs<\/em><br \/>\n<em>neuroendocrines et du syndrome carcino\u00efde<\/em> \u00bb a d\u00e9clar\u00e9 le Docteur Sotirios Stergiopoulos, Vice-<br \/>\nPr\u00e9sident Senior, Head of Global Medical Affairs (GMA) et Chief Medical Officer (CMO), Ipsen.<\/p>\n<p>Les pr\u00e9sentations sur Cabometyx\u00ae, Xermelo\u00ae, Somatuline\u00ae et 68Ga-OPS-202 sont bas\u00e9es sur les<br \/>\nr\u00e9sultats d\u2019\u00e9tudes investigationnelles.<\/p>\n<p><b>Lanr\u00e9otide (Somatuline\u00ae) est d\u00e9taill\u00e9 dans 4 posters :<\/b><\/p>\n<p>o Poster H19 \u2013 Cat\u00e9gorie : Medical Treatment \u2013 Chemotherapy Somatostatin Analogues, Interferon<br \/>\nTitre : Disease control in progressive pancreatic and intestinal neuroendocrine tumours by<br \/>\ncombined treatment with lanreotide autogel and temozolomide: the SONNET study<br \/>\nAuteurs : M. Pavel, U.-F. Pape, M. Raderer, A. Rinke, D. H\u00f6rsch, H. Lahner, T. Denecke, A.<br \/>\nKoch, N. Liyanage, A. Raspel<\/p>\n<p>o Poster J09 \u2013 Cat\u00e9gorie : Medical Treatment \u2013 Others Not Specified<br \/>\nTitre : Observational study of perception of information and quality of life in patients with<br \/>\nneuroendocrine tumor starting lanreotide \u2013 Study design<br \/>\nAuteurs : V. Hautefeuille, F. Bonnetain, D. Gueguen, A. Houchard, P. Hammel<\/p>\n<p>o Poster H14 \u2013 Cat\u00e9gorie : Medical Treatment \u2013 Chemotherapy Somatostatin Analogues, Interferon<br \/>\nTitre : Somatostatin Analog (SSA) Usage in Neuroendocrine Tumors (NETs): A Retrospective<br \/>\nDatabase Analysis with Supplemental Chart Review<br \/>\nAuteurs : A.J. Klink, B. Feinberg, H.T. Yu, D. Ray, S. Pulgar, A. Phan, A. Vinik<\/p>\n<p>o Poster K01 \u2013 Cat\u00e9gorie : Nuclear Medicine Imaging and Therapy (PRRT)<br \/>\nTitre : Influence of Lanreotide on Uptake of [68Ga]-DOTATATE in Patients with NETs<br \/>\nAuteurs : E.A. Aalbersberg, B.J. de Wi \u2013 van der Veen, L.J. Saveur,G.D. Valk, M.E.T. Tesselaar,<br \/>\nM.P.M. Stokkel<br \/>\n\u00c9tude men\u00e9e par un investigateur<\/p>\n<p><b>Cabozantinib (Cabometyx\u00ae) est trait\u00e9 dans 1 poster :<\/b><br \/>\no Poster I05 \u2013 Cat\u00e9gorie : Medical Treatment \u2013 Targeted Therapies<br \/>\nTitre : Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine<br \/>\ntumors<br \/>\nAuteurs : J. A. Chan, J. E. Faris, J. E. Murphy, L. S. Blaszkowsky, N. J. McCleary, J. A.<br \/>\nMeyerhardt, T. A. Abrams, S. Zhang, A. Reardon, B. Fitzpatrick, M. H. Kulke, D. P. Ryan<br \/>\n\u00c9tude men\u00e9e par un investigateur<\/p>\n<p><b>1 poster est consacr\u00e9 au t\u00e9lotristat (Xermelo\u00ae) :<\/b><br \/>\no Poster J06 \u2013 Cat\u00e9gorie : Medical Treatment \u2013 Others, Not Specified<br \/>\nTELESTAR\/TELECAST time to sustained BM improvement \u2013 \u201c[Lexicon-lead study]\u201d \u2013 Telotristat<br \/>\nTitre : Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl:<br \/>\nAnalyses of Two Phase 3 Studies in Carcinoid Syndrome<br \/>\nAuteurs : J. S. Dillon, M. H. Kulke, D. H\u00f6rsch, L. B. Anthony, R. R. P. Warner, E. Bergsland,<br \/>\nS. Welin, T. M. O\u2019Dorisio, P. L. Kunz, Chad McKee, P. Lapuerta, M. Pavel<br \/>\n\u00c9tude men\u00e9e par Lexicon<\/p>\n<p><b>1 poster est consacr\u00e9 au 68Ga-OPS202 :<\/b><br \/>\no Poster K25 \u2013 Cat\u00e9gorie : Nuclear Medicine Imaging and Therapy (PRRT)<br \/>\nTitre : Study to Evaluate the Optimal Dose of 68Ga-OPS202 as a PET Imaging Agent in Patients<br \/>\nwith GEP -NET<br \/>\nAuteurs : I. Virgolini, A. Brouwers, A. Haug , H. Gr\u00f8nb\u00e6k, A. Kj\u00e6r, D. Novac, A. Ang, C. Miller,<br \/>\nJ. Kaufmann, J. Czernin<\/p>\n<p><b>6 posters pr\u00e9sentent des donn\u00e9es dans des conditions r\u00e9elles :<\/b><br \/>\no Poster D53 \u2013 Cat\u00e9gorie : Epidemiology\/Natural History\/Prognosis \u2013 Registries, Nationwide and<br \/>\nRegional Surveys<br \/>\nTitre : Prevalence of Carcinoid Syndrome in the European Union: Systematic Review<br \/>\nAuteurs : G. Nayroles, A. Bergamasco, J. Mouchet, Y. Moride<\/p>\n<p>o Poster J05 \u2013 Cat\u00e9gorie :Medical Treatment<br \/>\nTitre : On-going Evaluation of the Use of Resources and the Costs (UR\/C) Associated with<br \/>\nControlled or Uncontrolled Carcinoid Syndrome (CS) in Patients (pts) with Neuroendocrine<br \/>\nTumours (NETs). RECOSY Study<br \/>\nAuteurs : A. Custodio, A. Carmona-Bayonas, C. Villabona, M. P\u00e9rez, G. de la Cruz, P. Jim\u00e9nez-<br \/>\nFonseca<\/p>\n<p>o Poster D05 \u2013 Cat\u00e9gorie : Medical Treatment \u2013 Epidemiology Natural History\/Prognosis \u2013<br \/>\nRegistries, Nationwide and Regional Surveys<br \/>\nTitre : Direct cost of metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NET)<br \/>\nGrade 1 or 2 (G1\/G2) in relation to time since diagnosis shows growing importance of<br \/>\nsomatostatin analogues (SSA)<br \/>\nAuteurs : D. Granfeldt, \u00c5. Bj\u00f6rstad, T. Marlow, J. Dinet, P. Myrenfors, E. Les\u00e9n, I. Bj\u00f6rholt, A-K.<br \/>\nElf, V. Johanson<\/p>\n<p>o Poster D06 \u2013 Cat\u00e9gorie : Epidemiology\/Natural History\/Prognosis \u2013 Registries, Nationwide and<br \/>\nRegional Surveys<br \/>\nTitre : Long-acting Somatostatin Analogue (LA-SSA) Treatment Durations in Patients Diagnosed<br \/>\nwith Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NET) Grade 1 or 2<br \/>\n(G1\/G2) in Sweden<br \/>\nAuteurs : D. Granfeldt, \u00c5. Bj\u00f6rstad, T. Marlow, J. Dinet, P.Myrenfors, E. Les\u00e9n, I. Bj\u00f6rholt, A-K.<br \/>\nElf, V. Johanson<\/p>\n<p>o Poster D77 \u2013 Cat\u00e9gorie : Epidemiology\/Natural History\/Prognosis \u2013 Registries, Nationwide and<br \/>\nRegional Surveys<br \/>\nTitre : Long-acting Somatostatin Analogue (LA-SSA) Treatment Patterns in Patients Diagnosed<br \/>\nwith Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NET) Grade 1 or 2<br \/>\n(G1\/G2) in Sweden<br \/>\nAuteurs : \u00c5. Bj\u00f6rstad, D. Granfeldt, T. Marlow, J. Dinet, P. Myrenfors, E. Les\u00e9n, I. Bj\u00f6rholt, A-K.<br \/>\nElf, V. Johanson<\/p>\n<p>o Poster H09 \u2013 Cat\u00e9gorie : Medical Treatment \u2013 Chemotherapy Somatostayin Analogues,<br \/>\nInterferon<br \/>\nTitre : Therapeutic sequences in patients with G1-G2 neuroendocrine tumors (NETs): an<br \/>\nobservational, multicentre, prospective\/retrospective study<br \/>\nAuteurs : A.A. Faggiano, S.A. Di Maio, S.B Tafuto, C.C Mocerino, A.D Di Sarno, G.E Palmieri,<br \/>\nI.F Puliafito, I.G De Luca, V.H Guarnotta, S.I Leo, L.J Tozzi, A.A Colao<br \/>\n\u00c9tude men\u00e9e par un investigateur<\/p>\n<p><b>2 posters pr\u00e9sentent des donn\u00e9es sur les TNE et le syndrome carcino\u00efde :<\/b><br \/>\no Poster J13 \u2013 Cat\u00e9gorie : Medical Treatment, Others Not Specified<br \/>\nTitre : Patient and Clinician Perspectives on Symptom Priorities across the Spectrum of<br \/>\nNeuroendocrine Tumors (NETs)<br \/>\nAuteurs : K.A. Kaiser, K.A. Webster, S. Shaunfield, G.J. Greene, S.E. Yount, L. Lacson, A.B.<br \/>\nBenson III, D.M. Halperin, M. Feuilly, F. Marteau, and D. Cella<br \/>\n\u00c9tude men\u00e9e par un investigateur<\/p>\n<p>o Poster D20 \u2013 Cat\u00e9gorie : Epidemiology\/Natural History\/Prognosis \u2013 Registries, Nationwide and<br \/>\nRegional Surveys<br \/>\nTitre : Carcinoid syndrome open questions \u2013 Evaluations from a real life setting<br \/>\nAuteurs : R. Fijalkowski, A. Singh, R. Baum, H. Kulkarni, K. Niepsch, D. Kaemmerer, M.<br \/>\nHommann, D. Hoersch<br \/>\n\u00c9tude men\u00e9e par un investigateur<\/p>\n<p><b>2 posters sont consacr\u00e9s \u00e0 la qualit\u00e9 de vie et \u00e0 l\u2019exp\u00e9rience des patients :<\/b><br \/>\no Poster D59 \u2013 Cat\u00e9gorie : Epidemiology\/Natural History\/Prognosis \u2013 Registries, Nationwide and<br \/>\nRegional Surveys<br \/>\nTitre : Patient survey devoted to characterizing experience and expectations of patients with<br \/>\nNeuroendocrine Tumors (NET)<br \/>\nAuteurs : M. Sarabi, D. Gueguen, E. Baudin<br \/>\no Poster J08 \u2013 Cat\u00e9gorie : Medical treatment, Others Not Specified<br \/>\nTitre : Clinical Utility (CU) Evaluation of the Health-Related Quality-Of-Life (HRQoL) QLQGINET21<br \/>\nQuestionnaire (QNR) in the Treatment of Patients (pts) with Gastrointestinal (GI)<br \/>\nNeuroendocrine Tumours (NETs). QUALINETS Study<br \/>\nAuteurs : J. Gallego, O. Reig, J. Sastre, I. Garc\u00eda, A. Segura, J. Capdevila, A. Carmona, I.<br \/>\nSevilla, T. Alonso, G. Crespo, L. Garc\u00eda, D. Arnau, G. de la Cruz, M. Benavent<\/p>\n<p><b>Pr\u00e9diction de la r\u00e9ponse aux ASS :<\/b><br \/>\no Poster F08 \u2013 Cat\u00e9gorie : Biomarkers<br \/>\nTitre : Plasma Protein hK14 Strongly Predict Pronounced Chromogranin A Response in Small<br \/>\nIntestinal Neuroendocrine Tumor Patients After Somatostatin Analog Treatment: The Nordic<br \/>\nEXPLAIN Biomarker Study<br \/>\nAuteurs : M. Kjellman, U.Knigge, S.Welin, H.Gronbaek, E.This-Evensen, H.Sorbye, MT<br \/>\nJ\u00f8rgensen, V. Johansson, S. Metso, K.Becker, T. Str\u00f6m, P.Myrenfors, R. Belusa and The<br \/>\nNordic NET Biomarker Group<\/p>\n<p><img src='https:\/\/ml-eu.globenewswire.com\/media\/MGZlODIzYzMtYThjOC00ZTQ4LWI4MWUtYjJjNDA4MDNmYzhmLTEwMTA5NDM=\/tiny\/Ipsen-SA.png' \/><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[1233,3556],"tags":[],"class_list":["post-36976","press_release","type-press_release","status-publish","hentry","category-pressrelease-fr","category-corporate-pressrelease-fr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen annonce la pr\u00e9sentation de 18 posters lors de la 15e conf\u00e9rence annuelle de l\u2019ENETS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen annonce la pr\u00e9sentation de 18 posters lors de la 15e conf\u00e9rence annuelle de l\u2019ENETS\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-06T16:43:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/MGZlODIzYzMtYThjOC00ZTQ4LWI4MWUtYjJjNDA4MDNmYzhmLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/\"},\"author\":{\"name\":\"IPSEN\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\"},\"headline\":\"Ipsen annonce la pr\u00e9sentation de 18 posters lors de la 15e conf\u00e9rence annuelle de l\u2019ENETS\",\"datePublished\":\"2018-03-06T07:00:00+00:00\",\"dateModified\":\"2023-09-06T16:43:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/\"},\"wordCount\":1329,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/MGZlODIzYzMtYThjOC00ZTQ4LWI4MWUtYjJjNDA4MDNmYzhmLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"articleSection\":[\"Communiqu\u00e9 de presse\",\"Corporate\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/\",\"name\":\"Ipsen annonce la pr\u00e9sentation de 18 posters lors de la 15e conf\u00e9rence annuelle de l\u2019ENETS\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/MGZlODIzYzMtYThjOC00ZTQ4LWI4MWUtYjJjNDA4MDNmYzhmLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"datePublished\":\"2018-03-06T07:00:00+00:00\",\"dateModified\":\"2023-09-06T16:43:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/#primaryimage\",\"url\":\"https:\/\/ml-eu.globenewswire.com\/media\/MGZlODIzYzMtYThjOC00ZTQ4LWI4MWUtYjJjNDA4MDNmYzhmLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"contentUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/MGZlODIzYzMtYThjOC00ZTQ4LWI4MWUtYjJjNDA4MDNmYzhmLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen annonce la pr\u00e9sentation de 18 posters lors de la 15e conf\u00e9rence annuelle de l\u2019ENETS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\",\"name\":\"IPSEN\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"caption\":\"IPSEN\"},\"sameAs\":[\"https:\/\/www.ipsen.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen annonce la pr\u00e9sentation de 18 posters lors de la 15e conf\u00e9rence annuelle de l\u2019ENETS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/","og_locale":"fr_FR","og_type":"article","og_title":"Ipsen annonce la pr\u00e9sentation de 18 posters lors de la 15e conf\u00e9rence annuelle de l\u2019ENETS","og_url":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/","og_site_name":"Global","article_modified_time":"2023-09-06T16:43:27+00:00","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/MGZlODIzYzMtYThjOC00ZTQ4LWI4MWUtYjJjNDA4MDNmYzhmLTEwMTA5NDM=\/tiny\/Ipsen-SA.png"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/"},"author":{"name":"IPSEN","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0"},"headline":"Ipsen annonce la pr\u00e9sentation de 18 posters lors de la 15e conf\u00e9rence annuelle de l\u2019ENETS","datePublished":"2018-03-06T07:00:00+00:00","dateModified":"2023-09-06T16:43:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/"},"wordCount":1329,"publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/MGZlODIzYzMtYThjOC00ZTQ4LWI4MWUtYjJjNDA4MDNmYzhmLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","articleSection":["Communiqu\u00e9 de presse","Corporate"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/","url":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/","name":"Ipsen annonce la pr\u00e9sentation de 18 posters lors de la 15e conf\u00e9rence annuelle de l\u2019ENETS","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/MGZlODIzYzMtYThjOC00ZTQ4LWI4MWUtYjJjNDA4MDNmYzhmLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","datePublished":"2018-03-06T07:00:00+00:00","dateModified":"2023-09-06T16:43:27+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/#primaryimage","url":"https:\/\/ml-eu.globenewswire.com\/media\/MGZlODIzYzMtYThjOC00ZTQ4LWI4MWUtYjJjNDA4MDNmYzhmLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","contentUrl":"https:\/\/ml-eu.globenewswire.com\/media\/MGZlODIzYzMtYThjOC00ZTQ4LWI4MWUtYjJjNDA4MDNmYzhmLTEwMTA5NDM=\/tiny\/Ipsen-SA.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-la-presentation-de-18-posters-lors-de-la-15e-conference-annuelle-de-lenets\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Ipsen annonce la pr\u00e9sentation de 18 posters lors de la 15e conf\u00e9rence annuelle de l\u2019ENETS"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0","name":"IPSEN","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","caption":"IPSEN"},"sameAs":["https:\/\/www.ipsen.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36976","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":2,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36976\/revisions"}],"predecessor-version":[{"id":36981,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36976\/revisions\/36981"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=36976"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/categories?post=36976"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/tags?post=36976"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}